Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2013 Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor Arthritis Rheum 2013; In press
2. 2013 Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase 2, randomized, double-blind, placebo-controlled, dose-ranging study J Rheumatol 2013; In press
3. 2012 Racial/ethnic differences in receiving biologic DMARD treatment among California Medicaid rheumatoid arthritis patients. Arthritis Care Res 2012; doi: 10.1002/acr.21798 Epub 2012 July 17
4. 2012 Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum 2012; 64: 1610 – 1619
5. 2012 Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis 2012; 71: 1289 – 1296
6. 2012 Belimumab reduces autoantibodies, normalizes low complement, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2328 – 2337
7. 2012 Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol 2012; 39: 1632 – 1640
8. 2012 Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data Health Econ 2012; doi: 10.1002/hec.2855 Epub 2012 Jun 21
9. 2012 Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Ann Rheum Dis 2012; 71: 1567 – 1572.
10. 2012 The discovery and development of belimumab: the anti-BLyS–lupus connection. Nat Biotechnol 2012; 30: 69 – 77. (PMID 22231104; PMCID 3264947)
11. 2012 Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep 2012; 14: 303 – 309
12. 2012 Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE Ann Rheum Dis 2012; 71: 351 – 357
13. 2011 Cytokine disturbances in systemic lupus erythematosus Arthritis Res Ther 2011; 13: 228.
14. 2011 Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside Curr Opin Rheumatol 2011; 23: 305 – 310. (
15. 2011 Antibody-mediated coengagement of FcgRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus J Immunol 2011; 186: 4223 – 4233
16. 2011 Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011; 70: 39 – 46.
17. 2011 B cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice J Immunol 2011; 186: 4984 – 4993.
18. 2011 BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS ONE 2011; 6: e23629.
19. 2011 A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918 – 3930
20. 2010 Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther 2010; 12: 111.
21. 2010 Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future Autoimmunity 2010; 43: 84 – 97
22. 2010 Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity Arthritis Rheum 2010; 62: 2432 – 2442
23. 2010 . Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-b/a ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort Arthritis Rheum 2010; 62: 392 – 401.
24. 2009 Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1768 – 1774
25. 2009 Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway J Immunol 2009; 182: 2532 – 2541.
26. 2009 B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients Arthritis Rheum 2009; 60: 3400 – 3409
27. 2009 Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61: 1143 – 1151
28. 2009 A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus Arthritis Rheum 2009; 61: 1168 – 1178
29. 2009 Deficiency of type I IFN receptor in lupus-prone New Zealand Mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 2009; 183: 6021 – 6029.
30. 2009 Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study Arthritis Res Ther 2009; 11: R143
31. 2008 B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response Ann Rheum Dis 2008; 67: 1011 – 1016.
32. 2008 Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus Arthritis Rheum 2008; 58: 2453 – 2459
33. 2008 Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity
34. 2008 Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus Arthritis Res Ther 2008; 10: R109
35. 2008 B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor a antagonists: differential effects between good and poor clinical responders. Ann Rheum Dis 2008; 67: 1132 – 1138
36. 2007 New and promising treatments for rheumatoid arthritis Am J Orthop 2007; 36 (7 Suppl): 18 – 23.
37. 2006 B cell depletion therapy in systemic rheumatic diseases: Different strokes for different folks? Clin Immunol 2006; 121: 1 – 12
38. 2006 B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with BLyS protein levels Arthritis Res Ther 2006; 8: R6
39. 2006 Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse Arthritis Rheum 2006; 54: 723 – 732.
40. 2006 TGF­­-β requires CTLA‑4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol 2006; 176: 3321 – 3329.
41. 2006 Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand Mixed 2328 mice deficient in BAFF Immunol 2006; 177: 2671 – 2680.
42. 2006 Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases Endocr Metab Immune Disord Drug Targets 2006; 6: 351 – 358
43. 2006 Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI). Biochem Biophys Res Commun 2006; 349: 838 – 845
44. 2005 B Cell Trophic Factors and B Cell Antagonism in Autoimmune Disease Current Directions in Autoimmunity (series editor, Theofilopoulous AN), Vol 8, Karger, Basel, 2005, pp 1 – 304
45. 2005 BLySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists Curr Dir Autoimmun 2005; 8: 289 – 304
46. 2005 Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II. Clin Immunol 2005; 116: 257 – 264.
47. 2005 BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus Arthritis Rheum 2005; 52: 2080 – 2091
48. 2005 Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis Ann Rheum Dis 2005; 64: 743 – 749
49. 2004 Inverse association between circulating APRIL levels and serologic and clinical disease activities in patients with systemic lupus erythematosus Ann Rheum Dis 2004; 63: 1096 – 1103.
50. 2004 Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol 2004; 155: 161 – 171.
51. 2004 A therapeutic role for BLyS antagonists. Lupus 2004; 13: 317 – 322
52. 2004 Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic diseases Expert Opin Ther Targets 2004; 8: 177 – 189
53. 2004 MHC class II-independent and ‑dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA‑4). Int Immunol 2004; 16: 895 – 904
54. 2004 Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone mice. Arthritis Rheum 2004; 50: 2227 – 2239
55. 2003 Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis Arthritis Rheum 2003; 48: 982 – 992.
56. 2003 Systemic lupus erythematosus: a BLySful, yet BAFFling, disorder Arthritis Res Ther 2003; 5: 136 – 138.
57. 2003 B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations Arthritis Rheum 2003; 48: 3475 – 3486
58. 2003 In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens Clin Immunol 2003; 108: 182 – 189
59. 2002 B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep 2002; 4: 345 – 350
60. 2002 BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases J Immunol 2002; 169: 4314 – 4321.
61. 2002 B lymphocyte stimulator-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Clin Immunol 2002; 104: 115 – 122.
62. 2002 Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein Curr Opin Rheumatol 2002; 14: 522 – 528
63. 2001 Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases Arthritis Rheum 2001; 44: 1313 – 1319.
64. 2001 In vivo staphylococcal superantigen-driven polyclonal Ig responses in mice: dependence upon CD4+ cells and human MHC class II Int Immunol 2001; 13: 1291 – 1300
65. 2001 Cell cycle phase-specific survival of CD95 ligand-challenged Jurkat cells: upregulation of heat-shock response Cell Immunol 2001; 211: 21 – 29
66. 2000 Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death Cell Immunol 2000; 203: 1 – 11
67. 1999 Impaired cytotoxic T lymphocyte activity in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: a contributory role for non-T cells. Lupus 1999; 8: 293 – 299.
68. 1998 Superantigen-driven, CD8+ T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cells. J Immunol 1998; 161: 3292 – 3298
69. 1998 CD95 (Fas)-based, superantigen-dependent, CD4+ T cell-mediated down-regulation of human in vitro immunoglobulin responses J Immunol 1998; 160: 5231 – 5238
70. 1997 Impaired nonrestricted cytolytic activity in systemic lupus erythematosus: involvement of a pathway independent of Fas, tumor necrosis factor, and extracellular ATP that is associated with little detectable perforin Arthritis Rheum 1997; 40: 1130 – 1137.
71. 1996 In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens Clin Immunol Immunopathol 1996; 79: 122 – 133.
72. 1996 Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: studies in unselected patients and monozygotic disease-discordant twins. Arthritis Rheum 1996; 39: 1840 – 1851.
73. 1995 Differential human T cell-dependent B cell differentiation induced by staphylococcal superantigens (SAg): regulatory role for SAg-dependent B cell cytolysis J Immunol 1995; 155: 1838 – 1850.
74. 1995 Impaired polyclonal T cell cytolytic activity: a possible risk factor for systemic lupus erythematosus Arthritis Rheum 1995; 38: 506 – 516.
75. 1994 Enhancing effects of interleukin 2-treated peripheral blood mononuclear cells on subsequent B cell differentiation Cell Immunol 1994; 157: 381 – 392.
76. 1994 Human T cell-dependent B cell differentiation induced by staphylococcal superantigens. J Immunol 1994; 153: 117 – 127.
77. 1994 Polyclonal in vitro T cell proliferation and T cell-dependent B cell differentiation supported by activated autologous B cells Clin Immunol Immunopathol 1994; 72: 44 – 52
78. 1992 Impaired generation of polyclonal T cell-mediated cytolytic activity despite normal polyclonal T cell proliferation in systemic lupus erythematosus Clin Immunol Immunopathol 1992; 63: 163 – 172.
79. 1992 Stimulation of human peripheral blood mononuclear cells with anti-CD3 monoclonal antibody vs IL2: disparate effects on T cell-dependent B cell differentiation despite similar effects on generation of unrestricted cytolytic activity Clin Immunol Immunopathol 1992; 65: 30 – 38.
80. 1991 Induction of human T cell proliferation by a monoclonal antibody to CD5. J Immunol 1991; 146: 47 – 52.
81. 1990 Differential CD3/T cell antigen receptor-mediated IL-2 production in Jurkat T cells: dissociation of IL-2 response from total inositol phosphate and calcium responses. J Immunol 1990; 145: 1078 – 1087.
82. 1990 Generation of cytolytic activity with anti-CD3 monoclonal antibodies involves both IL-2-independent and -dependent pathways J Immunol 1990; 144: 3718 – 3725.
83. 1990 Inhibition by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell-dependent B cell activation Cell Immunol 1990; 130: 257 – 270.
84. 1990 A novel role for accessory cells in T cell-dependent B cell differentiation. Cell Immunol 1990; 127: 458 – 469.
85. 1989 Characterization of lymphokines mediating B cell growth and differentiation from monoclonal anti-CD3 antibody-stimulated T cells J Immunol 1989; 142: 2343 – 2351.
86. 1989 Feedback inhibition of B cell differentiation by monomeric immunoglobulin Int Rev Immunol 1989; 5: 189 – 195
87. 1989 A functionally unique anti-CD3 monoclonal antibody cross-reactive with basal keratinocytes Cell Immunol 1989; 121: 247 – 260.
88. 1989 Human peripheral blood T helper cell-induced B cell activation results in B cell surface expression of the CD23 (BLAST-2) antigen. Cell Immunol 1989; 121: 99 – 112.
89. 1989 Inhibitory effects of anti-CD2 monoclonal antibodies on interleukin 2 production and interleukin 2 receptor expression in anti-CD3-induced T cell activation. Cell Immunol 1989; 120: 351 – 365.
90. 1989 Treatment of systemic lupus erythematosus with intravenous gammaglobulin Immunol Updates 1989; 1: 1 – 2
91. 1988 In vitro induction of T cell-dependent B cell differentiation in patients with common varied immunodeficiency Clin Immunol Immunopathol 1988; 49: 273 – 282.
92. 1988 Differential immunomodulation by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell activation: dependence upon the individual anti-CD3 monoclonal antibody used for activation Cell Immunol 1988; 116: 73 – 85.
93. 1987 Inhibition of human B cell proliferation and B cell differentiation by polyspecific monomeric IgG Clin Exp Immunol 1987; 70: 649 – 657.
94. 1987 Correlation between systemic lupus erythematosus and T4 epitope phenotype Arthritis Rheum 1987; 30: 1412 – 1415.
95. 1987 Induction of T cell-dependent B cell differentiation by anti‑CD3 monoclonal antibodies. J Immunol 1987; 138: 1667 – 1673
96. 1986 Modulation of the immune response by immunoglobulin for intravenous use. II. Inhibitory effects of sera from treated patients Clin Immunol Immunopathol 1986; 41: 273 – 280
97. 1986 Cellular mechanisms in the in vitro inhibition of pokeweed mitogen‑induced B cell differentiation by immunoglobulin for intravenous use J Immunol 1986; 136: 4407 – 4413
98. 1985 Systemic lupus erythematosus with deficiency of the T4 epitope on T helper/inducer cells. New Engl J Med 1985; 312: 1671 – 1678.
99. 1985 Modulation of the immune response by immunoglobulin for intravenous use. I. Inhibition of pokeweed mitogen‑induced B cell differentiation Clin Exp Immunol 1985; 62: 200 – 207.
100. 1984 Heterogeneity in expression of the T4 epitope in black individuals Scand J Immunol 1984; 20: 273 – 278.
101. 1980 Detection of the precursor and effector cells of experimental allergic encephalomyelitis in the thoracic duct of the rat Cell Immunol 1980; 54: 471 – 477.
102. 1979 A quantitative assay for experimental allergic encephalomyelitis in the rat based on permeability of spinal cords to 125I‑human γ-globulin J Immunol 1979; 122: 920 – 925.
103. 1978 Chronic permeability of the central nervous system to mononuclear cells in experimental allergic encephalomyelitis in the Lewis rat J Immunol 1978; 121: 844 – 850. (PMID 308523)
104. 1977 Distribution of the Thy‑1 antigen in cellular and subcellular fractions of adult mouse brain J Immunol 1977; 119: 422 – 427.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.